NCT05985954View on ClinicalTrials.gov

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

March 28, 2028

Study Completion Date

March 28, 2028

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab

Given by IV (vein)

DRUG

Ulixertinib

Given by PO

DRUG

Encorafenib

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05985954 - Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Biotech Hunter | Biotech Hunter